Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
MultiCell Technologies (MCET)
:MCET
MCET Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
―
Mutual Funds
0.14% Other Institutional Investors
99.86% Public Companies and
Individual Investors
MCET FAQ
What was MultiCell Technologies ’s price range in the past 12 months?
Currently, no data Available
What is MultiCell Technologies ’s market cap?
MultiCell Technologies ’s market cap is $5.00K.
When is MultiCell Technologies ’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were MultiCell Technologies ’s earnings last quarter?
Currently, no data Available
Is MultiCell Technologies overvalued?
According to Wall Street analysts MultiCell Technologies ’s price is currently Overvalued.
Does MultiCell Technologies pay dividends?
MultiCell Technologies does not currently pay dividends.
What is MultiCell Technologies ’s EPS estimate?
MultiCell Technologies ’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MultiCell Technologies have?
MultiCell Technologies has 5,000,949,000 shares outstanding.
What happened to MultiCell Technologies ’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of MultiCell Technologies ?
Currently, no hedge funds are holding shares in MCET
---
Company Description
MultiCell Technologies
MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company. The firm develops novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer. Its therapeutic development platform includes several patented techniques used to isolate, characterize and differentiate stem cells from human liver or control the immune response at transcriptional and translational levels through dsRNA-sensing molecules, such as Toll-like receptor, RIG-I-like receptor, and MDA-5 signaling. The company was founded on April 28, 1970 and is headquartered in Woonsocket, RI.
---
Ibio
―
Galectin Therapeutics
―
Northwest Biotherapeutics
―
Actinium Pharmaceuticals
―
Anavex Life Sciences
―
---